Does hyperprolactinemia treatment affect pregnancy and perinatal outcomes?

Autor:	Santos AC; University of Campinas, School of Medicine - Campinas (SP), Brazil., Yela DA; University of Campinas, School of Medicine - Campinas (SP), Brazil.; University of Campinas, School of Medical Sciences, Department of Obstetrics and Gynecology - Campinas (SP), Brazil., Nakamura RM; University of Campinas, School of Medicine - Campinas (SP), Brazil.; University of Campinas, School of Medical Sciences, Department of Obstetrics and Gynecology - Campinas (SP), Brazil., Ribas BC; University of Campinas, School of Medicine - Campinas (SP), Brazil., Silva PHRE; University of Campinas, School of Medicine - Campinas (SP), Brazil., Mota B; University of Campinas, School of Medicine - Campinas (SP), Brazil., Benetti-Pinto CL; University of Campinas, School of Medicine - Campinas (SP), Brazil.; University of Campinas, School of Medical Sciences, Department of Obstetrics and Gynecology - Campinas (SP), Brazil.
Jazyk:	angličtina
Zdroj:	Revista da Associacao Medica Brasileira (1992) [Rev Assoc Med Bras (1992)] 2024 Nov 11; Vol. 70 (10), pp. e20240634. Date of Electronic Publication: 2024 Nov 11 (Print Publication: 2024).
DOI:	10.1590/1806-9282.20240634
Abstrakt:	Objective: The aim of this study was to assess obstetric and perinatal outcomes in women with hyperprolactinemia according to the type of treatment indicated, with cabergoline or bromocriptine. Methods: A retrospective cohort study with 464 women diagnosed with hyperprolactinemia was undertaken at the endocrine gynecology outpatient clinic of a tertiary hospital from May 2002 to February 2022. All women diagnosed with hyperprolactinemia who were being treated with dopamine agonists (cabergoline or bromocriptine) and who became pregnant during the follow-up were included. Women whose medical records did not provide data related to pregnancy and delivery were excluded. The women were divided into two groups according to the type of treatment: bromocriptine or cabergoline. Clinical and laboratory characteristics and obstetric and perinatal outcomes, such as complications during pregnancy, type of delivery, and intrapartum complications, were evaluated in both groups. Results: Of the 464 women evaluated, 72 became pregnant during the follow-up, 66 of them were using dopamine agonists, while 6 were not using medication. The mean age of the women was 28.3±6.8 years. Among the causes of hyperprolactinemia, 48.6% were idiopathic, 45.7% were tumoral, and 3.7% had other causes. Most women with idiopathic hyperprolactinemia used bromocriptine, while those with tumoral hyperprolactinemia used cabergoline (p=0.04). There was no difference in obstetric outcomes according to the type of treatment used. The majority of women did not have any complications during pregnancy (76.3%) or intrapartum (86.8%). Conclusion: Regardless of the type of previous drug treatment with dopamine agonists, hyperprolactinemia does not alter obstetric outcomes.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu